Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Post by Bilderbergon Apr 15, 2024 6:20am
155 Views
Post# 35988792

Schedule 3 Controlled Substances Import Permit DEA form 357

Schedule 3 Controlled Substances Import Permit DEA form 357

Application for permit to import Controlled Substances DEA Form 357 

DEA Form 357 - Application for Permit to Import Controlled Substances for Domestic and/or Scientific Purposes (PDF)

 

INFORMATION AND INSTRUCTIONS, DEA FORM 357

https://www.deadiversion.usdoj.gov/imp_exp/357/form-357.html

 

MJ will be added to the registration form soon…that, NAFTA and also the power of Big Pharma, Tilray will dominate the US prescription weed market after rescheduling.

 

The DEA has been dragging their feet since the FDA recommended to them that marijuana be reclassified to schedule 3 last summer.

But when the Vice President OTUS TELLS you to “act as quickly as possible” you’re gonna need to do just that…

 

Last months closed door meeting at the White House most likely drastically sped up the DEA's decision and announcement for rescheduling…

 

Vice President Kamala Harris, who convened the meeting, shared an opening statement (which was broadcast publicly) in which she called on the U.S. Drug Enforcement Administration (DEA) to act “as quickly as possible” on cannabis’s scheduling review and said cannabis’s Schedule I classification under the Controlled Substances Act is “absurd and patently unfair,” 

But following the vice president’s opening statement, media attendees were asked to leave, and the remainder of the meeting took place behind closed doors.

https://www.cannabisbusinesstimes.com/news/vp-kamala-harris-we-need-to-legalize-marijuana-in-closed-door-meeting-interview-chris-goldstein/

 

And late last week (Thursday) in a congressional hearing the FDA Head Says There’s ‘No Reason For DEA To Delay’ Rescheduling Marijuana

https://www.marijuanamoment.net/watch-live-fda-commissioner-testifies-on-hemp-regulatory-issues-at-congressional-hearing/

 

DEA has all they need already:

 

FDA Releases Its Scientific Support for Rescheduling Marijuana to Schedule III

January 18th 2024

https://www.mcguirewoods.com/client-resources/alerts/2024/1/fda-releases-its-scientific-support-for-rescheduling-marijuana-to-schedule-iii/

 

Marijuana meets criteria for reclassification as lower-risk drug, FDA scientific review finds

January 12th 2024

https://amp.cnn.com/cnn/2024/01/12/health/marijuana-rescheduling-fda-review

 

One more thing, tomorrow could be Tax Relief Tuesday for Tilray after a parliamentary finance committee proposed capping excise taxes at 10% of the value of a marijuana product.

Simon said Tilray would save $80 million annually if that recommendation were implemented. 

 

Feds here in Canada need to support what they started and not let the weed industry keep suffering and this is one simple measure that will be a huge positive for this industry when it needs it the most!

 

Cheers, have a great week )

<< Previous
Bullboard Posts
Next >>